两会·履职感悟:黄璐琦:中医药学科创新急需国家重点实验室

2018-03-09 栗征 中国中医

没有一个正式的中医药学科国家重点实验室,一直是中医药科技工作者心中的痛。

没有一个正式的中医药学科国家重点实验室,一直是中医药科技工作者心中的痛。


国家重点实验室是国家科技创新体系的重要组成部分,其主要任务是针对学科发展前沿和国民经济、社会发展及国家安全的重要方向开展创新性研究。近10年来,国家重点实验室产出了50%以上的国家自然科学奖、30%以上的国家技术发明奖、20%以上的国家科技进步奖。据科技部2015国家重点实验室年度报告,截至2015年底,正在运行的国家重点实验室共255个,其中生物和医学领域75个。

中国中医科学院常务副院长黄璐琦委员带领“中医药科技创新体系建设”项目组对包括国家重点实验室在内的各类国家科技创新基地进行了政策研究。研究发现,目前中医药行业只有7家国家重点实验室,且均为企业国家重点实验室,着重于提升企业自主创新能力和核心竞争力,缺少开展基础研究、提升学科原始创新能力的学科国家重点实验室。而这些已有企业国家重点实验室的研究方向全部集中在中药相关领域,在中医理论、疾病机理与针灸等中医药重点研究领域还没有国家重点实验室布局。

“当前中医药科技创新还面临许多困难和问题,科研基地与科技基础条件保障综合实力建设相对薄弱,缺乏顶层设计和统筹,为科研创新提供手段和支撑的能力不足是较为凸显的问题之一。”黄璐琦对此感到十分忧虑,中医药学科国家重点实验室建设的空白,不仅极大制约了中医药现代化发展的步伐,也不利于中医药创新驱动发展与服务“健康中国”建设等国家战略。因此,他提交了关于在优化科技创新基地布局中创建中医药国家重点实验室的提案,建议依托中医药高等院校和科研院所,在中医药、针灸、中西结合等基础研究领域部署建设一批国家重点实验室。同时,对现有中医药国家重点实验室培育基地进行评估考核,对评估考核通过、运行良好的培育基地纳入国家重点实验室建设范围。

《中医药发展战略规划纲要(2016—2030年)》把“着力推进中医药创新,健全中医药协同创新体系”列为重点任务。国家中医药管理局《关于加快中医药科技创新体系建设的若干意见》提出“到2030年建成符合中医药自身发展规律和特点、适应我国经济社会发展和中医药事业发展需求、科技创新关键要素完备、运行协调高效的中医药科技创新体系”。政策的出台让黄璐琦更加意识到创新的紧迫,他表示,中医药行业急需面向国家战略需求、国际科技前沿与中医药重大科学问题,在全国范围内科学设计与合理布局,凝练发展目标和研究方向,汇聚国内外高水平、多学科科技资源与力量,建设包括国家重点实验室在内的重大科技平台,形成中医药自主创新与多学科、多部门协同创新的国际一流创新研究平台。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1957453, encodeId=e052195e453c0, content=<a href='/topic/show?id=5fe04098847' target=_blank style='color:#2F92EE;'>#国家重点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40988, encryptionId=5fe04098847, topicName=国家重点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Fri Apr 06 13:05:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285542, encodeId=48dd128554221, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409407, encodeId=8c09140940e0f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585278, encodeId=0ced15852e838, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294578, encodeId=e51a2945e876, content=加大中医药科学研究势在必行., beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 09 16:59:04 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1957453, encodeId=e052195e453c0, content=<a href='/topic/show?id=5fe04098847' target=_blank style='color:#2F92EE;'>#国家重点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40988, encryptionId=5fe04098847, topicName=国家重点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Fri Apr 06 13:05:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285542, encodeId=48dd128554221, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409407, encodeId=8c09140940e0f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585278, encodeId=0ced15852e838, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294578, encodeId=e51a2945e876, content=加大中医药科学研究势在必行., beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 09 16:59:04 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1957453, encodeId=e052195e453c0, content=<a href='/topic/show?id=5fe04098847' target=_blank style='color:#2F92EE;'>#国家重点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40988, encryptionId=5fe04098847, topicName=国家重点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Fri Apr 06 13:05:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285542, encodeId=48dd128554221, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409407, encodeId=8c09140940e0f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585278, encodeId=0ced15852e838, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294578, encodeId=e51a2945e876, content=加大中医药科学研究势在必行., beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 09 16:59:04 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-11 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1957453, encodeId=e052195e453c0, content=<a href='/topic/show?id=5fe04098847' target=_blank style='color:#2F92EE;'>#国家重点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40988, encryptionId=5fe04098847, topicName=国家重点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Fri Apr 06 13:05:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285542, encodeId=48dd128554221, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409407, encodeId=8c09140940e0f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585278, encodeId=0ced15852e838, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294578, encodeId=e51a2945e876, content=加大中医药科学研究势在必行., beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 09 16:59:04 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1957453, encodeId=e052195e453c0, content=<a href='/topic/show?id=5fe04098847' target=_blank style='color:#2F92EE;'>#国家重点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40988, encryptionId=5fe04098847, topicName=国家重点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Fri Apr 06 13:05:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285542, encodeId=48dd128554221, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409407, encodeId=8c09140940e0f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585278, encodeId=0ced15852e838, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sun Mar 11 06:05:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294578, encodeId=e51a2945e876, content=加大中医药科学研究势在必行., beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 09 16:59:04 CST 2018, time=2018-03-09, status=1, ipAttribution=)]
    2018-03-09 1e0f8808m18(暂无匿称)

    加大中医药科学研究势在必行.

    0

相关资讯

两会·现场 “中医药的源头活水在基层”

全国政协十三届一次会议开幕会结束后,全国两会启动首场“部长通道”。国家中医药管理局局长王国强在接受记者采访时表示,“一带一路”倡议实施以来,很多国家对中医药产生了浓厚兴趣。目前,中医药已在183个国家和地区得到运用,86个国家的政府同我国签订中医药相关协定,我国在国外建立了17个中医药中心,制定了一批国际中医药标准,建立了一批中医药“走出去”战略合作基地,中医药服务贸易呈现良好发展态势,中医药还应

政协医卫界联组会议:委员就传承发展中医药献策

3月6日下午,出席全国政协十三届一次会议的医卫界别政协委员联组讨论政府工作报告,并结合本界别工作实际,就推进健康中国战略实施、传承发展中医药事业等议题建言献策。

中医药文化价值远大于治疗价值,文化建设迫在眉睫

“中医药文化的价值远远大于中医药治疗的价值。”全国政协委员、中国中医科学院西苑医院肿瘤治疗部主任杨宇飞在提案最开头郑重其事地写下这句话。一线临床医生群体中,把中医药文化价值上升到如此高度的人,并不多见。

2018年山东中医药工作会:借力新旧动能转换,提升发展效率

日前,2018年山东省中医药工作会议在济南召开。会议全面贯彻落实全国中医药工作会议和全省卫生计生工作会议精神,回顾总结2017年工作,研究部署2018年重点任务,着力推动新时代山东中医药事业振兴发展。

两会聚焦:"支持中医药事业传承发展",中医药界政协委员展开热议

国务院总理李克强在十三届全国人大一次会议开幕式上作政府工作报告,强调“支持中医药事业传承发展”,中医药界政协委员们就此展开热议——

两会:宁波市副市长许亚南代表:中医药走出去要拓展服务贸易

在“一带一路”倡议中推进中医药走出去,既是经济贸易,也是文化传播,对促进我国经济发展、提升国际文化影响力和认同感、共同维护人类健康具有重要作用。全国人大代表、宁波市副市长许亚南对如何加快推进中医院参与“一带一路”倡议进行了专题调研,并提出了合理建议。